Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Organovo Holdings Inc vs. United Therapeutics Corporation

By Brian Stoffel - Feb 26, 2016 at 10:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

While one company has dazzling potential, the other is a smarter bet right now.

Both Organovo and United Therapeutics are focused on solving some of the world's most complex medical problems. Image source: Pixabay

Investing in cutting-edge healthcare stocks isn't for the faint of heart. Companies can go from having no revenue to a blockbuster drug in no time at all -- and investors can reap untold gains. Or a start-up can go belly up and investors lose everything. The line between the two can oftentimes seem perilously thin.

Organovo (ONVO -5.85%) and United Therapeutics (UTHR -0.79%) are two companies on the cutting edge of healthcare technology. Organovo has developed a 3-D bioprinter that helps create liver (and soon, kidney) cells in vivo that mimic native cell behavior. Drug companies then use these cells to test for toxicity long before clinical trials start -- helping them potentially save billions of dollars and potentially even human lives.

United Therapeutics, on the other hand, is a larger company that has found success focusing on developing treatments for life-threatening diseases. Nearly 70% of the company's revenue last quarter came from two drugs: Remodulin, an injection for pulmonary arterial hypertension (PAH), and Tyvaso, which treats the same condition through an inhaler.

Which is the better buy today? Let's evaluate three key dimensions.

Financial fortitude
Investors need to be keenly aware of a company's balance sheet. Though cash on hand and debt levels aren't the be-all, end-all of an investment thesis, these figures play an important role. Lots of cash on hand, with more coming in, allows a company to be flexible, while debt makes them more fragile in the face of unexpected challenges.

Let's consider a few key metrics for each company.


Market Cap


Long-Term Debt

Net Income

Free Cash Flow


$220 million

$70 million


($38.1 million)

($29.8 million)

United Therapeutics

$5.9 billion

$922 million

$30 million

$663 million

$428 million

Source: Yahoo! Finance. Net Income and FCF are for trailing 12 months.

While it might be reassuring that Organovo holds $70 million in cash against absolutely no long-term debt, this doesn't tell the whole story. Organovo has only one marketable product -- its exVive 3D Liver Assay -- and even that has brought in very little revenue to date.

The company burned through $30 million in cash over the past year, and CEO Keith Murphy recently warned that though no dilutive offerings would be necessary in the next 24 months, they weren't out of the question for the future.

United Therapeutics, on the other hand, is solidly profitable, has lots of cash against little debt, and has no problem with free cash flow.

Winner: United Therapeutics

Here's where things get tricky. United Therapeutics has shown that it can effectively target a field -- here, PAH -- and reap the financial rewards from it. The company is also targeting cancer-related and infectious-disease treatments, though these two have shown much less in terms of revenue generation thus far.

In fact, in terms of addressing the near-, medium-, and long-term potential of the company, management focuses solely on treatments for PAH, including the two aforementioned drugs, as well as a newer treatment, Orenitram. Ironically, United Therapeutics has teamed up with Organovo in the past to further research such treatments.

For Organovo, bulls would have you believe that the sky is the limit. Indeed, management believes that Organovo can one day generate over $100 million per year in revenue (versus just $1.2 million in 2015) from its liver and kidney assays alone. But it's important to note that over the next two years, liver and kidney cell assays are the only products Organovo will probably have -- and it probably won't reach that full potential by the end of 2017.

That said, I'll give a cautious nod to Organovo, as its 3-D bioprinter gives the company -- for now -- a virtual monopoly on in vivo, bioprinted cells. While $100 million itself is less than United Therapeutics pulls in during a quarter, Organovo is also worth less than $200 million. If the company can reach even a fraction of its potential in (1) selling its in vivo cells, (2) developing some of its own drugs, or (3) monetizing its NovoGen bioprinter, it could be worth many multiples of its current market cap.

Winner: Organovo

There are lots of popular ways to measure profitability, but many of them don't apply in this situation because Organovo has yet to turn a profit or generate positive free cash flow. Since Organovo isn't expected to be profitable until 2020, the only apples-to-apples comparison we can really make is price-to-sales. On that mark, United Therapeutics is the runaway winner, trading at 4 times sales, versus Organovo's 166 times sales.

Winner: United Therapeutics

Ten years from now, it's entirely possible than an investment in Organovo will end up being the more profitable purchase right now. But we can't predict the future, so using the information that's on hand right now, United Therapeutics seems to clearly be a better buy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

United Therapeutics Corporation Stock Quote
United Therapeutics Corporation
$238.95 (-0.79%) $-1.91
Organovo Holdings, Inc. Stock Quote
Organovo Holdings, Inc.
$1.77 (-5.85%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.